Pasithea Therapeutics Corp.
KTTA
$0.57
-$0.03-4.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 33.55% | 29.59% | 23.55% | 0.21% | -13.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.89% | 28.80% | 17.14% | -14.12% | -18.72% |
| Operating Income | -43.89% | -28.80% | -17.14% | 14.12% | 18.72% |
| Income Before Tax | -58.22% | -45.03% | -46.91% | 14.36% | 17.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.22% | -45.03% | -46.91% | 14.36% | 17.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.22% | -45.03% | -46.91% | 14.46% | 17.88% |
| EBIT | -43.89% | -28.80% | -17.14% | 14.12% | 18.72% |
| EBITDA | -46.01% | -30.15% | -17.86% | 14.83% | 19.46% |
| EPS Basic | 80.69% | 81.57% | 72.92% | 64.86% | 48.23% |
| Normalized Basic EPS | 84.94% | 84.61% | 75.47% | 64.78% | 48.12% |
| EPS Diluted | 80.69% | 81.57% | 72.92% | 64.86% | 48.23% |
| Normalized Diluted EPS | 84.94% | 84.61% | 75.47% | 64.78% | 48.12% |
| Average Basic Shares Outstanding | 655.12% | 803.90% | 540.17% | 279.90% | 122.10% |
| Average Diluted Shares Outstanding | 655.12% | 803.90% | 540.17% | 279.90% | 122.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |